

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Dupilumab for treating adults with severe atopic dermatitis [ID1048]**

**Batch 53**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

During consultation it was raised that the assessment scales for the severity of atopic dermatitis may underestimate disease severity in people from some skin colours. Skin colour has been included as a subgroup in the scope.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

It is possible that the assessment tool for assessing the severity of atopic dermatitis and the response to treatment may not be sensitive enough in people with some skin colours. This should be explored with the clinical experts at committee.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

Skin colour has been added as a subgroup

4. Have any additional stakeholders related to potential equality issues

been identified during the scoping process, and, if so, have changes to the matrix been made?
---

Not applicable.
-----------------

**Approved by Associate Director (name):** Elisabeth George

**Date:** 28/09/2017